News

ACT would like to welcome Somesh Nigam to our Editorial Advisory Board and introduce him to our readers.

Photo highlights from ExL Pharma's September Conference: Merging eHR & EDC.

Release takes adverse event reporting to a new level, complies with FDA's new rules

Document management suite gets training records tool with eCTD capabilities slated for V4.0

What has the industry and the FDA accomplished this year and what still needs to be done?

From stress levels to job satisfaction, ACT's first salary survey provides an inside look at our industry today.

CEO transition positions Medifacts for growth and expansion

AAIPharma Completes CAC Acquisition

ClinPhone Acquires DataLabs

Robert Davidson

A detailed history of the billion-dollar industry since its inception in 1986 and what the future may hold.

A detailed history of the billion-dollar industry since its inception in 1986 and what the future may hold.

A listing of clinical laboratories arranged alphabetically, with addresses and contact details.

Phase I package adds formulary accountability, recruitment, lab, and EDC features

Phase I package adds formulary accountability, recruitment, lab, and EDC features

Regulatory submission solution addresses the needs of smaller biotech and pharma companies

Phase I package adds formulary accountability, recruitment, lab, and EDC features

System enables IRB members to review ?s in near real-time from anywhere in the world

A listing of clinical laboratories arranged alphabetically, with addresses and contact details.

UAB Launches Promising Brain Tumor Trial

Tools for Clinical Trials Professionals

Tools for Clinical Trials Professionals

Tools for Clinical Trials Professionals

What do the G8 Summit, national security, and the pharmaceutical industry have in common?

Allied Research International (ARI), Canada's leading contract research organization (CRO), announced today that it has acquired key assets of South Florida Bioavailability Clinic International's (SFBC) Miami, Florida operations.

Tools for Clinical Trials Professionals

Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its financial results for the second quarter of 2006.

Shire plc announced today that it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for SPD465, an investigational amphetamine compound for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in the adult population.